187 related articles for article (PubMed ID: 11567982)
1. Systemic therapy of myeloma xenografts by an attenuated measles virus.
Peng KW; Ahmann GJ; Pham L; Greipp PR; Cattaneo R; Russell SJ
Blood; 2001 Oct; 98(7):2002-7. PubMed ID: 11567982
[TBL] [Abstract][Full Text] [Related]
2. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.
Dingli D; Peng KW; Harvey ME; Greipp PR; O'Connor MK; Cattaneo R; Morris JC; Russell SJ
Blood; 2004 Mar; 103(5):1641-6. PubMed ID: 14604966
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.
Peng KW; Donovan KA; Schneider U; Cattaneo R; Lust JA; Russell SJ
Blood; 2003 Apr; 101(7):2557-62. PubMed ID: 12433686
[TBL] [Abstract][Full Text] [Related]
4. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
5. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
[TBL] [Abstract][Full Text] [Related]
6. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression.
Hallak LK; Merchan JR; Storgard CM; Loftus JC; Russell SJ
Cancer Res; 2005 Jun; 65(12):5292-300. PubMed ID: 15958576
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice.
Grote D; Russell SJ; Cornu TI; Cattaneo R; Vile R; Poland GA; Fielding AK
Blood; 2001 Jun; 97(12):3746-54. PubMed ID: 11389012
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
[TBL] [Abstract][Full Text] [Related]
9. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
11. Enhancing cytokine-induced killer cell therapy of multiple myeloma.
Liu C; Suksanpaisan L; Chen YW; Russell SJ; Peng KW
Exp Hematol; 2013 Jun; 41(6):508-17. PubMed ID: 23403007
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
Liu C; Russell SJ; Peng KW
Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340
[TBL] [Abstract][Full Text] [Related]
13. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.
Xia M; Gonzalez P; Li C; Meng G; Jiang A; Wang H; Gao Q; Debatin KM; Beltinger C; Wei J
J Virol; 2014 May; 88(9):5152-64. PubMed ID: 24574393
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma.
Meng X; Nakamura T; Okazaki T; Inoue H; Takahashi A; Miyamoto S; Sakaguchi G; Eto M; Naito S; Takeda M; Yanagi Y; Tani K
Mol Ther; 2010 Mar; 18(3):544-51. PubMed ID: 20051938
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
16. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
17. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
[TBL] [Abstract][Full Text] [Related]
19. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy.
Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J
J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779
[TBL] [Abstract][Full Text] [Related]
20. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
Anderson BD; Nakamura T; Russell SJ; Peng KW
Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
